Generalisable Overview of Study Risk for Lead Investigators Needing Guidance (GOSLING): A data governance risk tool.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 12 05 2024
accepted: 08 08 2024
medline: 20 8 2024
pubmed: 20 8 2024
entrez: 20 8 2024
Statut: epublish

Résumé

Digitisation of patient records, coupled with a moral imperative to use routinely collected data for research, necessitate effective data governance that both facilitates evidence-based research and minimises associated risks. The Generalisable Overview of Study Risk for Lead Investigators Needing Guidance (GOSLING) provides the first quantitative risk-measure for assessing the data-related risks of clinical research projects. GOSLING employs a self-assessment designed to standardise risk assessment, considering various domains, including data type, security measures, and public co-production. The tool categorises projects into low, medium, and high-risk tiers based on a scoring system developed with the input of patient and public members. It was validated using both real and synthesised project proposals to ensure its effectiveness at triaging the risk of requests for health data. The tool effectively distinguished between fifteen low, medium, and high-risk projects in testing, aligning with subjective expert assessments. An interactive interface and an open-access policy for the tool encourage researchers to self-evaluate and mitigate risks prior to submission for data governance review. Initial testing demonstrated its potential to streamline the review process by identifying projects that may require less scrutiny or those that pose significant risks. GOSLING represents the first quantitative approach to measuring study risk, answering calls for standardised risk assessments in using health data for research. Its implementation could contribute to advancing ethical data use, enhancing research transparency, and promoting public trust. Future work will focus on expanding its applicability and exploring its impact on research efficiency and data governance practices.

Identifiants

pubmed: 39163388
doi: 10.1371/journal.pone.0309308
pii: PONE-D-24-18657
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0309308

Informations de copyright

Copyright: © 2024 Arora et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Anmol Arora (A)

School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.

Adam Loveday (A)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Sarah Burge (S)

Department of Oncology, Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.

Amy Gosling (A)

University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Ari Ercole (A)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Sarah Pountain (S)

University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Helen Street (H)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.

Stephanie Kabare (S)

University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

Raj Jena (R)

Department of Oncology, University of Cambridge, Cambridge, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH